Home › Compound Library › Methamphetamine

Methamphetamine

Stimulantoral · inferred

Potent CNS stimulant that releases dopamine, norepinephrine, and serotonin. N-demethylated to amphetamine (active metabolite). Half-life ~10 hours but highly pH-dependent: acidic urine shortens to ~7 hours, alkaline urine extends to ~30 hours. Detectable in urine for 3-5 days.

Projected serum levels — 10 mg, as needed (shown daily)

Methamphetamine
Methamphetamine modeled serum levels, 10 mg as needed (shown daily) over 15 days Population-based pharmacokinetic estimate. Steady state reached after approximately 1 days. 0 2.5 5 7.5 10 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule ≈ steady state · day 1
Methamphetamine modeled serum levels with a loading dose of 12.6 mg, then 10 mg as needed (shown daily) The first dose is larger so levels approach steady state faster. 0 2.5 5 7.5 10 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule

Maintenance schedule: 10 mg as needed (shown daily) (oral).

Loading schedule: 12.6 mg on day 1, then 10 mg as needed (shown daily) — reaching therapeutic levels sooner.

Modeled steady state after ~1 days: peak ≈ 6.6 mg, trough ≈ 1.7 mg body load. Population-based estimate over 15 days for a 10 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Stimulant
Route modeled
Oral
Model confidence
inferred
Half-life
10 h
Common dose
10 mg
Reference dose range
2.5–25 mg (single dose)
Suggested cadence
as needed (shown daily)
Validated against
30 mg oral — Cmax 0.060 mg/L at 3.5 h

Documented interactions

  • danger
    1P-LSD (1-Propionyl-LSD) + Methamphetamine Serotonin risk

    1P-LSD (1-Propionyl-LSD) and Methamphetamine both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

  • danger
    25I-NBOMe + Methamphetamine Serotonin risk

    25I-NBOMe and Methamphetamine both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

  • danger
    2C-I (2,5-Dimethoxy-4-iodophenethylamine) + Methamphetamine Serotonin risk

    2C-I (2,5-Dimethoxy-4-iodophenethylamine) and Methamphetamine both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

  • danger
    2C-B (4-Bromo-2,5-dimethoxyphenethylamine) + Methamphetamine Serotonin risk

    2C-B (4-Bromo-2,5-dimethoxyphenethylamine) and Methamphetamine both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

  • danger
    3-MeO-PCP (3-Methoxyphencyclidine) + Methamphetamine Serotonin risk

    3-MeO-PCP (3-Methoxyphencyclidine) and Methamphetamine both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

  • danger
    4-AcO-DMT (Psilacetin) + Methamphetamine Serotonin risk

    4-AcO-DMT (Psilacetin) and Methamphetamine both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

Serum checks 175 modeled interaction pairings for methamphetamine across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

  1. Urinary Pharmacokinetics of Methamphetamine and Its Metabolite, Amphetamine Following Controlled Oral Administration to Humans Kim I et al. · Therapeutic Drug Monitoring, 2004 DOI

    Determined urinary elimination half-lives of 23.6 h for methamphetamine and 20.7 h for amphetamine metabolite after controlled oral methamphetamine dosing in humans.

  2. Methamphetamine and Amphetamine Pharmacokinetics in Oral Fluid and Plasma after Controlled Oral Methamphetamine Administration to Human Volunteers Schepers RJF et al. · Clinical Chemistry, 2003 DOI

    Characterized methamphetamine and amphetamine in plasma and oral fluid after 10 and 20 mg oral doses, with peak plasma concentrations of 14.5-44.3 ug/L within 2-12 hours.

  3. A Review of the Clinical Pharmacology of Methamphetamine Cruickshank CC, Dyer KR · Addiction, 2009 DOI

    Comprehensive review covering methamphetamine absorption, hepatic N-demethylation to amphetamine (active metabolite), para-hydroxylation, and renal excretion influenced by urinary pH.

3 published studies referenced in the app, each with a plain-language summary.